Pharmaceutical company Moderna Inc (NASDAQ: MRNA) announced on Tuesday that it has achieved successful Phase 3 trial results for mRNA-1283, its next-generation COVID-19 vaccine. Compared to its licensed vaccine mRNA-1273.222, mRNA-1283 induces a stronger immune response against SARS-CoV-2, particularly in individuals over 65.
The NextCOVE trial involved over 11,400 participants aged 12 and above across the US, UK and Canada. mRNA-1283 demonstrates a similar safety profile to Moderna's approved COVID-19 vaccines.
mRNA-1283's storage, shelf life, and pre-filled syringe presentation could ease healthcare provider burden and enhance accessibility in various settings. Detailed trial data will be presented at Moderna's Vaccines Day event on 27 March 2024.
Moderna's mRNA platform has revolutionised medicine development, delivering rapid and efficient solutions for infectious diseases, immuno-oncology, rare diseases and autoimmune conditions. The company's mission is to create a healthier future through innovative mRNA medicines.
Gilead expands global access to lenacapavir for HIV prevention
Lunaphore partners with Discovery Life Sciences
Priovant Therapeutics enrols first patients in brepocitinib CLARITY study
TC BioPharm plans Proof of Concept preclinical studies of TCB 008 for treatment of monkey pox
SIFI's AKANTIOR receives European Commission approval
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation
RedHill Biopharma launches Talicia in UAE for H. pylori treatment
RedHill Biopharma reports promising results for opaganib in obesity and diabetes studies